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Lassa fever (LF) and Ebola Hemorrhagic Fever (EHF) are viral diseases endemic to West              
Africa.The etiological agent of Lassa fever is an enveloped virus from the ​Arenaviridae family              
and was first discovered in 1969 when two missionary nurses died of a mysterious illness in the                 
town of Lassa in Borno state, Nigeria.​1 This virus is animal-borne (zoonotic) and is carried by                
the animal vector ​Mastomys natalensis (multimammate rat). The Ebola virus is also zoonotic             
originating from fruit bats belonging to the ​Pteropodidae family.​2 ​The first reported case of              
Ebola Virus Disease (EVD) was a principal who was believed to have visited the Ebola river on                 
his journey through the Democratic Republic of Congo.  
Annually, there are about 100,000 to 300,000 reported cases of Lassa fever, with about              
5,000 deaths.​1 Concurrently, the Ebola virus has raked in 11,310 reported deaths from about              
28,616 suspected cases, 10% of which were health professionals.​3 It is noteworthy, however, that              
the death toll associated with EVD is more sporadic and widespread than that of LF. Most                
infections can be attributed to person-person transmission in which healthy individuals get            
infected by coming in contact with the body fluids (urine, saliva, and semen) of the sick.​1 
Both the Lassa and Ebola viruses are pertinent in current public health discussions             
especially for their potential as bioweapons.​1,2 Consequently, this paper seeks to discuss the             
structure and pathogenic mechanisms of both viruses, address current treatments and           
complications, and propose areas for further research and preventive measures. 
 
Keywords:​Lassa virus (LASV), Ebola Virus (EBOV), Lassa Fever (LF), Ebola Virus Disease            






TABLE OF CONTENTS 
Chapter One: Introduction………………………………...……………………………..4 
Part I: The Lassa Virus​………………………………………………………….....4 
Part II: The Ebola Virus​……………………………………………………..….....9 
Chapter Two:Literature Review....……………………..……………………………......13 
Part I : What Do We Know?​...……………………..………………………….......13 
Part II: Where Can We Go?​.………………………………………………….......18 
Chapter Three: Conclusion….…………………….....…………………………….…….26 
References……………….……………………………..…………………………....…….28 
 
LIST OF FIGURES 
Figure 1: Lassa Virus (LASV).........…………………………………………………...….4 
Figure 2: ​Mastomys natalensis​, the primary host of the LASV ...……………..…….….4 
Figure 3: Map of West Africa………………………………………………………..........5 
Figure 4: Ribavirin: an analogue of Guanosine..………………………………....……...6 
Figure 5: Proposed mechanisms of Ribavirin action on HCV……………………..........7 
Figure 6: Map of Central Africa……………….…………………..………...………...….9 
Figure 7: Ebola Virus (EBOV)...……………………….……………………………...…10 
Figure 8: Fruit bat (primary host of EBOV)……………….……………………....……11 
Figure 9: Immune response…….....………....……………………………………………13 
Figure 10: EBOV mechanisms……......…..…...………………….………………………15 
Figure 11: Cytokine storm………..……………………………………...………..………16 
Figure 12: Systemic organ damage as a result of sepsis………..……....………..………17 
Figure 13: The macroscopic anatomy of the human ear.………………..……………....19 
Figure 14:BAER test showing normal hearing…..…………………………………....…22 
Figure 15: Visual representation of Specific Aim I………....…..…………....…..………22 
Figure 16: Sample of test results expected for Specific Aim I………..…………….……23 
Figure 17: Visual representation of Specific Aim II....………..…………..……..….....…24 







Part I: The Lassa Virus 
The Lassa virus   
(LASV) is an   
enveloped virus  
belonging to the   
genus Arenavirus  
and the family   
Arenaviridae​.​5,6 
Like other viruses,   
the LASV infects a host organism      
(typically humans) and hijacks cell     
machinery thereby causing the cells to create more viruses that go on to infect other cells.​6 
The genome of LASV consists of two single-stranded RNA species designated small (S)             
and large (L) which is characteristic of all arenaviruses         
(see Figure 1).​7,8,9 Arenaviruses are divided into two        
groups based on their rodent hosts: the New World         
arenaviruses and the Old World arenaviruses.​9,10 The       
Mastomys natalensis (commonly called the     
multimammate rat) is the primary host of       
the LASV (see Figure 2).​11 Its habitats       






(LF), which is a hemorrhagic fever caused by LASV is endemic in West African countries like                
Nigeria, Sierra Leone, Liberia, and Guinea where these rats and their habitats are prevalent (see               
Figure 3).​12 It was first discovered in 1969 when two missionary nurses died in Nigeria and                
received its name from the     
town called Lassa in    
Northern Nigeria where these    
first cases occurred.​13   
Humans presumably become   
infected through contact with    
infected rodent excreta,   
tissues, or blood.​8   
Person-to-person 
transmission of Lassa fever    
can also occur.​9 ​Additionally,    
pregnant women in the    
third-trimester are most susceptible to contracting the virus. Between January 1996 and March             
1997, over 1,000 cases of Lassa fever with 148 deaths were reported from eastern Sierra               
Leone.​14,15 
Additionally, many of the countries affected by this disease are also endemic regions for malaria               
epidemics.​16,17 Unfortunately, malaria presents with similar symptoms as Lassa fever does.​17           
Some of the symptoms include fatigue, general weakness, fever, headache, and a sore throat              






with LF like vomiting, diarrhea, face swelling, low blood pressure, and nose bleeding can also be                
misdiagnosed as Dengue or Yellow Fever.​19 Thus, the only sure-fire diagnostic method is by              
using enzyme-linked immunosorbent serologic assays (ELISA), which detect IgM and IgG           
antibodies as well as the Lassa antigen.​5 It was discovered that these antigens have minute               
variations depending on the origins of the viral isolates.​20 Using genomic sequencing they were              
able to categorize these strains into three groups, namely the prototype LP strain from              
northeastern Nigeria,​11 the GA 391 strain from central Nigeria,​12 and the Josiah strain from Sierra               
Leone.​10 The LP strain is also called the native LASV strain because it is predominantly found in                 
the town of Lassa, Borno State where the virus was first discovered.​20  
Regardless of the viral strain, however, there is currently only one way to treat a LASV                
infection.​18 The disease has no cure or vaccine, but experimentation continues to be done on               
monkeys like ​Cynomolgus macaques ​because their response to the virus has been most similar to               
humans. Researchers have avoided mice models because they are too close to the host species               
Mastomys natalensis ​and thus do not      
have an immunogenic response to the      
virus.​15 
​Additionally, Ribavirin which    
was initially approved as a treatment      
for severe respiratory syncytial virus     
(RSV) in children has been found to       
alleviate the symptoms of LF.​20 This      






sugar which is involved in a variety of cellular function including the synthesis of nucleic acids                
and proteins, as an ATP substitute, and in intracellular signal transduction).​20 ​Twenty years after              
its initial discovery, in the early 1990s, Ribavirin began to be used as a monotherapy treatment                
for Hepatitis C Virus (HCV).​20 At least half of the patients treated with Ribavirin had               
improvements in their serum aminotransferase levels, but the viral levels of HCV in these              
patients did not relent even after prolonged treatment.​21  
Apart from direct antiviral effects Ribavirin has been found to have immunomodulatory            
ones as well. In patients, Ribavirin induced a switch in T-helper (T​H​) cells from T​H​2 to T​H​1 (see                  
Figure 5 mechanism a).​22 ​Helper T cells are important players in the adaptive immune system.               
T​H​1 cells  
specifically are  
pro-inflammatory 
which means they   
secrete cytokines  
that increase the   
inflammatory 
response.​22 These  
cytokines, 
interferon-​γ ​(IFN-​γ​)  
and ​tumor necrosis   
factor-α (​TNF-​α),  






Once inside the cell, Ribavirin is phosphorylated to its GMP, GDP, and GTP analogues which               
are RMP, RDP, and RTP respectively.​22,23 Research by Maag et al. showed that a              
misincorporation of RTP by RNA polymerase in place of GTP can block RNA elongation and               
lead to premature termination which would inhibit viral spread (see Figure 5 mechanism c.).​22              
This only occurs at high concentrations of the drug, however, so it was assumed that this was not                  
the main mechanism of action in HCV infections.​22 Another possible candidate for the Ribavirin              
mechanism is its action as a competitive inhibitor of inosine monophosphate dehydrogenase            
(IMPDH) (Figure 5 mechanism b).​22 IMPDH is an enzyme that catalyzes the rate-limiting step of               
GTP and ATP synthesis:inosine-5-phosphate (IMP) to xanthosine monophosphate (XMP) which          
is subsequently converted to GMP/AMP by GMP/AMP synthetase.​22 Consequently, Ribavirin          
leads to the depletion of GTP which is necessary for viral RNA synthesis.​23 
Unlike human polymerases that check and recheck RNA/DNA to ensure the fidelity of             
the transcripts, HCV RNA polymerase is less concerned about mutations because they are             
usually beneficial to the virus.​23 Crotty et al. proposed that ribavirin might act as a viral mutagen                 
and increase the frequency of mutations in the virus (Figure 5 mechanism d).​24 At some point,                
these mutations become detrimental to the virus and lead to “error catastrophe”.​24,25            
Unfortunately, studies have shown that these mechanisms are not effective enough to completely             
stem a viral load.​23,24 Thus current treatments with Ribavirin are supplemented with interferon             
alpha (IFN- ).​26 IFN- induces IFN-stimulating genes which establish a non-virus-specific          
antiviral state with the infected cell which eventually lead to protein degradation, inflammatory             
cell responses and apoptosis.​26 When administered together, Ribavirin seems to amplify or            






All things considered, scientists are still unsure how the drug works on the LASV, but it                
is suspected that the drug might be acting on the viral RNA and blocking its translation to                 
proteins in the host cells either by mechanisms b or c pictured in Figure 5.​27 Additionally, the                 
drug only seems to have this effect if administered early in the infection which could be due to                  
the fact that the virus has not had much time to replicate or spread systemically allowing                
Ribavirin to effectively depress viral     
activity. ​27 
Part II: Ebola Virus 
Ebola, also known as the Ebola      
Virus Disease (EVD) or Ebola     
Hemorrhagic Fever (EHF) is a severe and       
often fatal disease in humans.​28 The      
Ebola virus (EBOV) was first discovered      
in 1976 when there were two      
simultaneous outbreaks in the towns of Nzara, South Sudan and Yambuku, Democratic Republic             
of Congo as shown in Figure 6.​28 The disease actually got its name from the Ebola river in                  
Congo.​28 The Ebola virus belongs to the Filoviridae family in which there are five different               
variants or species: Zaire (EBOV), Bundibugyo (BDBV), Sudan (SUDV), Reston (RESTV), and            
Tai Forest (TAFV).​28 The first three have been associated with large outbreaks in Africa, the               
most recent of which being the Zaire outbreak in West Africa in 2014.​28 
EBOV is a filamentous virion containing linear negative-stranded RNA.​29 The virus           






surface of the virus mediate the attachment of the virus to host cells and the subsequent fusion of                  
the viral and host membranes.​29 EBOV is       
believed to enter the cell via      
receptor-mediated endocytosis. Previously,   
it was believed that the VP24 and matrix        
VP40 proteins on the virus were minor       
structural components solely involved in     
viral nucleocapsid formation, viral budding     
or assembly, and host range determination.​28      
Current research, however, suggests that VP24 might be involved in blocking interferon            
signaling. Interferons are signaling proteins released by infected host cells in response to the              
presence of viruses, bacteria, parasites, or tumor cells.​29 These interferons act as warning signals              
to neighbouring cells alerting them of a potential infection.​30 It is assumed that the other               
components of the virion structure including its nucleoprotein(N), VP35,VP30, and L proteins            
are involved in stabilizing the RNA in its helical conformation.​28  
Much like the Lassa virus, the Ebola virus is transmitted from animals to humans and               
through the human population by contact with contaminated surfaces or materials like bedding or              
clothing that have been exposed to body fluids of infected individuals.​11,28 All strains of the virus                
except for RESTV are pathogenic to humans.​31 It is believed that the original (natural) hosts of                
the virus were fruit bats of the Pteropodidae family (Figure 8). It was introduced into the human                 
population by contact with the blood, organs, and other body fluids of infected chimps, gorillas,               






The incubation period for the virus is between 2 and 21 days and humans are not                
infectious until they present symptoms.​31 The      
first symptoms of an infection are very similar        
to those of Lassa fever, malaria, and other        
endemic illnesses and can only be effectively       
diagnosed using an ELISA; however, a major       
difference is the fact that the major complication        
of Ebola impair kidney and liver functions.​32 On        
average the fatality rate for an EVD infection is         
about 78% and the virus can survive in semen         
for between 3 and 12 months even after recovery. There is currently no cure or proven treatment                 
for EVD, but supportive care including rehydration with oral or intravenous fluids has been the               
most common way of maintaining patients.​32,33  
After the most recent outbreak of EVD in August 2014, research began on the              
recombinant vesicular stomatitis virus (rVSV). Vesicular stomatitis is a viral disease that            
primarily affects horses and cattle, but can also be harmful to swine, sheep, goats, and llamas.​34                
Humans are rarely affected by this disease even when they come into contact with infected               
animals, however, the recombinant form of VSV has been mutated to express the filovirus              
glycoprotein (GP): rVSV-ZEBOV. ​Upon administration to monkeys it was found that it            
protected them from Ebola and Marburg virus infections both as a prophylactic and             
postexposure.​35 As of April 2016, phase trials for the rVSV-ZEBOV vaccine had begun in              






deltoid at different concentrations and it was noted that 11 of the 51 participants in Geneva                
complained of arthralgia and developed skin lesions.​36 ​Nonetheless, they discovered high levels            
of neutralizing antibodies in the blood plasma which lasted in the blood for about 180 days.​36                
This research holds promise because it suggests that the recombinant virus is immunogenic in              
humans and the next step would be to test how effectively these antibodies bind to and neutralize                 






















 CHAPTER TWO: LITERATURE REVIEW 
Part I: What Do We Know?  
Viral Mechanisms and Pathogenesis 
While the Lassa and Ebola viruses belong to different virus families they share             
similarities in their mechanisms of pathogenesis.​37 ​In vitro experiments suggest that both viruses             
infect macrophages and endothelial cells at the onset of the infection.​37 Macrophages and             
endothelial cells play an important role in the innate immune system. The innate immune system               
is the body’s general response to a pathogen.​38 It is considered the next line of defense after a                  
pathogen or foreign substance has     
already passed through the skin or the       
mucosa lining the body’s    
orifices.​38 The innate response    
is nonspecific and involves a     
variety of proteins (interferons,    
antimicrobial proteins, and   
complement) and phagocytic   
cells (like neutrophils and    
macrophages) which recognize   
foreign antigens and quickly    
activate the inflammatory   
response (Figure 9). The inflammatory response is activated when these phagocytic cells as well              






that attract other important immune cells (like B and T Lymphocytes) to the infected area (Figure                
9).​39 It is believed that both the Lassa and Ebola viruses activate similar innate response               
pathways and trigger the rapid and uncontrolled release of cytokines, or inflammatory            
mediators.​40 ​Dendritic cells (DCs) are also key players of the innate immune system because they               
act as antigen presenting cells to B and T lymphocytes.​40 Current research show that both viruses                
have contradicting effects on these different cell populations ie. they activate macrophages and             
endothelial cells to release cytokines and activate an immune response, while they use DCs to               
replicate and inhibit them from releasing cytokines or synthesizing the costimulatory proteins            
necessary for antigen presentation.​40 ​This also serves to slow down or possibly inhibit the              
adaptive immune response to the infection. 
The mechanism for the Lassa Virus is the least understood of the two, however more               
recent research showed that T-cells play a dual role of not only protecting the infected organism                
from LASV, but also in enhancing LF pathogenesis.​35 ​In this experiment the scientists used              
genetically engineered (HHD) mice which were susceptible to LF because they had human T              
cells.​41 This theory is supported by the fact that macrophages also act as antigen presenting cells                
and the costimulatory effects of the T cells they bind to can further activate them to secrete                 
inflammatory mediators, thereby increasing the immune response.​41 ​In the case of Lassa fever, it              
seems that it is postulated that with increasing viremia, T cells continue to encounter LASV               
epitopes on the macrophages and thus continue to stimulate them as well.​41 This overstimulation              
of the macrophages leads to severe hepatic and pulmonary damage, in addition to the shock               
syndrome associated with Lassa Fever. Mammalian studies have further supported this theory by             






than low ones.​42 This might seem to contradict the previous experiment, but in reality it follows                
the kinetic model of proteins.​42 In the sense that there is a concentration at which the virus                 
reaches its maximum virility. At that point all the T cells are “exhausted” and are no longer                 
available to overstimulate the macrophages.​42 This attenuates the disease making it less fatal.             
Thus, on the one hand it seems that the adaptive immune system is a necessary part of the battle                   
against the virus and on the other it might increase its adverse effects.​42 
Similar to the LASV, the Ebola Virus initially infects macrophages and dendritic cells.​43             
One characteristic difference between the two, however, is the fact that Ebola presents with a               
cytokine storm, which is typical of many hemorrhagic diseases.​43 A cytokine storm is a secretion               
of numerous pro-inflammatory   
cytokines and induces contradictory    
signals that adversely affect immune     
cells and other tissues of the body.​43       
The Ebola virus seems to primarily      
affect the spleen and kidneys in      
addition to the immune system. This      
is important to note because these two organs are involved in maintaining the body’s fluid and                
chemical balance as well as the blood supply of coagulation factors.​44 Additionally, the EBOV is               
able to invade almost all human cells by using attachment mechanisms like receptor-mediated             
endocytosis and macropinocytosis (Figure 10). Viral activation leads to a steady increase in the              
production of proinflammatory cytokines and chemokines including IL-1​β​, IL-1RA, IL-6, IL-8,           






progression also leads to the nitric oxide production which dilates and increases the permeability              
of blood vessels.​45 These changes trigger the coagulation cascade which leads to widespread             
elevated thrombomodulin and   
ferritin levels. Thrombomodulin   
is a protein cofactor expressed     
on endothelial cell surfaces.​46 ​Its     
function is to modify thrombin     
which is an essential component     
of the coagulation pathway.    
Thrombin is the enzyme that     
converts fibrinogen to fibrin which     
eventually forms the fibrous mesh     
associated with a clot.​46 Ferritin is an intracellular protein that stores iron.​46 Excess amounts of               
these proteins play a role in the formation of blood clots (Disseminated Intravascular             
Coagulation; DIC) that could possibly inhibit the flow of blood to vital organs like the liver,                
brain, or kidneys which could lead to the tissue damage associated with EVD.​46 
Given the fact that the Ebola virus is on average more lethal than the Lassa virus, the                 
major complication associated with this disease is sepsis.​31 Sepsis can be defined as the systemic               
inflammatory response to an infection.​31 It can cause a variety of responses from shock, and               
multiple organ failure to death.​31 ​EBOV activates classical sepsis in which pattern recognition             
receptors like toll-like receptors (TLRs) or nucleotide-binding oligomerization domain         






























Part II: Where Can We Go?  
Future Studies and Research Proposal 
Of the two viruses Ebola has received the most recognition with global research efforts              
focusing on vaccines and treatment regimes for a virus that could potentially be a pandemic               
someday. The Lassa virus which is more prevalent in third world countries does not receive the                
same amount of interest either due to lack of funding from the failing health sectors of West                 
Africa, or a general disinterest in something that is not as “imminently” threatening as Boko               
Haram terrorist, famine, malaria, or drought. For this reason, it is important that West Africa               
begins a conversation on the subject of Lassa fever and how to eradicate it from the society.  
One of the biggest complications of Lassa fever is hearing loss. Statistics show that of the                
people infected with the LASV, 25% will develop hearing loss.​10 Unlike the other             
symptoms/complications of the disease like hypovolemic shock or hemmoraghing which can be            
accounted for by the viral mechanism of action ​in vivo​, no one really understands what happens                
in the progression of the disease to cause hearing loss.​10 
Virus-associated hearing loss is not a new concept in virology. Many viruses including              
the West Nile Virus, the mumps virus, the Varicella Zoster virus, and the measles virus have all                 
been found to cause some degree of sensorineural hearing loss in infected patients.​47-50 In these               
cases, the hearing loss is as a result of an acute infection and occurs as soon as the subjects are                    
exposed to the virus.​50 Additionally, the patient spontaneously recovered his or her ability to hear               
once the infection has passed. Some LASV associated hearing loss has been reported to behave               
in this manner as a result of an acute infection, but sometimes patients have been found to                 






that this could be a result of an autoimmune response resulting from the virus activating immune                
cells in the infected patients.​51 In these cases, even though the viral titer was low, the activated                 
immune cells were primed and ready to attack the ear leading to sensorineural hearing loss.​51  
The dynamics of the immune system and the role it plays in the propagation of the                
disease has been identified as a potential factor in the occurrence of the most common               
complication of LF: Sensorineural Hearing Loss (SNHL). Hearing, or auditory perception, is the             
ability to perceive sound by detecting vibrations in the surrounding air.​50 The pinna directs sound               
waves through the external auditory canal to the tympanic membrane all of which are part of the                 
outer ear (see Figure 13).​50 At the tympanic membrane sound vibrations are transmitted to the               
ossicles of the middle ear which amplify the sound before it gets to the cochlea.​50-51 Hair cells in                  
the cochlea (the inner ear) are involved in transducing that sound wave into electrical impulses               
that can be transmitted through the      
vestibulocochlear nerve to the temporal     
lobe of the brain where it is       
perceived as sound.​52  
Sound waves can be    
classified based on their    
frequencies and intensities.​52   
The frequency of a sound is      
measured in hertz (Hz) and     
dictates its pitch. The range for      






clapping between 2,200 and 2,800Hz, and the sound from crickets within the 4000-5000 Hz              
range.​53 The intensity of a sound is measured in decibels (dB) and it dictates how loud a sound is.                   
A whisper is about 15dB, a normal conversation about 60 dB, and a car horn is typically                 
110dB.​53 
Sometimes things can go wrong with the hearing process and hearing loss occurs. There              
are three types of hearing loss namely conductive, sensorineural, and mixed.​50 ​Conductive            
hearing loss affects the outer and middle ear and is characterized by foreign bodies or               
malformations that impede the sound waves from arriving at their destination.​52 Sensorineural            
hearing loss (SNHL), on the other hand, affects the inner ear and is also known as nerve-related                 
hearing loss. This type of hearing loss is usually caused by excessive exposure to loud noises,                
head trauma, viruses or diseases. SNHL also tends to be irreversible.​53,54 ​Finally, mixed hearing              
loss is a combination of both conductive and sensorineural hearing loss. Hearing loss can be               
measured as either an absolute inability to hear a certain sound frequency or as a degree of loss                  
that affects only sounds of certain intensities/loudness. 
Due to the fact that hearing loss is the most common and least understood complication               
of this disease and the goal of this proposal is to identify the presence or lack thereof of a                   












1. ​To determine what strains of the Lassa virus cause sensorineural hearing loss (SNHL) in               
Cynomolgus macaques​ with functional and depressed immune systems.  
Hypothesis: ​The combination of a heightened immune system and the most native strain of the               
Lassa virus (the NP strain) would increase the likelihood of hearing loss in the subjects. 
2. ​To test the effects of Ribavirin treatment on hearing loss in the affected group from the first                  
specific aim. 
Hypothesis:​ Ribavirin will have little to no effect on hearing loss unless administered early. 
Research Design and Methods 
The subject model for this experiment is the ​Cynomolgus macaque​. ​Cynomolgus           
macaques are a species of monkeys that have previously been used in studies with LASV               
because they have been found to respond to the virus with symptoms similar to humans.​15               
Researchers have avoided mice models because they are too close to the host species ​Mastomys               
natalensis ​and thus do not have an immunogenic response to the virus.​15  
I. The first specific aim is to determine what strains of the Lassa virus cause              
sensorineural hearing loss (SNHL) in ​Cynomolgus macaques with functional and          
depressed immune systems.  
A. The subject group would be 16 ​Cynomolgus macaques 
B. These ​macaques would all be initially exposed to the Brain Auditory Evoked Response             
(BAER) test in which they would have nodes put in their ears and a sound would be                 
released at a certain frequency (see Figure 14). The movement of the sound wave would               






midbrain. Once it is ensured that the subjects have functional hearing, they would be split               
into two groups with 8 ​macaques      
in each.  
C. One group of ​macaques would be      
given pure drinking water, while     
the other group will be given      
nicotine-spiked drinking water for    
a period of 2 weeks. Prior studies       
have shown that nicotine depresses     
the immune system, thus these ​macaques      
would constitute the immunosuppressed    
(IS) subject group with the other macaques being the immunocompetent (IC) group. 
D. The next step would be to divide the subjects once again into four groups: control, LP                
strain, GA391 strain, and the Josiah strain groups. The groups receiving the viral strains              
would be given 1 mL injections intravenously (see Figure 15). 
E. Subjects would be allowed to run      






weeks, and the hearing test would be performed weekly to determine if there is any               
hearing loss. 
Expected Results​:According to research conducted by Okokhere​12​, the majority of the           
documented hearing loss cases occurred in northeastern Nigeria. This area is where the NP or               
native strain of the LASV is prevalent. Thus, I would expect that the ​macaques exposed to this                 
strain would be most likely to develop hearing loss. Additionally, based on previous research              
which suggest that the immune system might play a role in the incidence of hearing loss.​18 I                 
would expect that the immunocompetent (IC)+NP strain would be even more likely to have              
hearing loss, or a greater degree of hearing loss than the immunosuppressed (IS)+NP strain. The               
presence of hearing loss would be identified by a BAER test similar to the right side result in                  
















II. The second specific aim is to test the effects of Ribavirin treatment on hearing loss in                
the affected group from the Specific Aim I. 
A. In this experiment, the subject group would be 16 ​macaques ​exposed to the same              
conditions as the subjects from the group in Specific Aim I that acquired hearing loss.  
B. These subjects would be split into groups of 4 . 
C. The groups would then be treated with 62.5 mg of Ribavirin daily for 10 days beginning                
at days 2,10, and 14 of the infection. The remaining 4 ​macaques would be the control                
with no Ribavirin treatment (see Figure 17).  
D. All subjects would undergo the BAER test weekly. In this experiment, they would be              
exposed to the same frequency at different decibel levels in order to determine the degree               
of hearing loss developed. 
Expected Results​: The treatment regimen of 62.5 mg was calculated based on the treatment for               
humans infected with the Lassa virus.​18 Currently, the drug is only effective in curbing the               
disease’s symptoms if administered early, thus I would expect that the group receiving the              
treatment at day two would have less severe hearing loss than those beginning the treatment at                






One of the biggest shortcomings of this experiment is the small sample size. Both              
specific aims use ​Cynomolgus macaques as subjects and while these organisms are ideal models              
because they respond to the virus with human-like symptoms, they are highly expensive to              
maintain. Thus, the results from this project might be a little skewed because of the small data                 
size. In order to address this, both specific        
aims could be attempted using knockout or       
transgenic mice. I would personally     
recommend transgenic mice over knockout     
mice because completely knocking out the      
immune system of these mice might allow       
them respond to the virus, but they might not         
live long enough to be valuable to the        
experiment. However, transgenic mice with     
human or macaque immune cell genes would       
still have functional immune systems that      
could manipulated as needed. This would allow       














CHAPTER THREE: CONCLUSION 
While Lassa fever and Ebola showed up in African history within the last century, 1969               
and 1979 respectively, they were both essentially forgotten until recent times.​55 Within the last              
couple of years there have been barely controlled epidemics of both viruses in West Africa.               
According to the World Health Organization (WHO), between August 2015 and May 2016 there              
were about 273 reported cases of Lassa Fever and 149 deaths in over 23 of the 36 states in                   
Nigeria.​55 Ebola took more lives in 2014 when there was a worldwide scare relating to an                
outbreak ravaging Guinea, Liberia, and Sierra Leone. A total of 28,616 cases were reported and               
about 11,310 deaths.​55 While the Lassa fever epidemic was restricted to African countries where              
the host rat is prevalent, a total of four individuals were infected in America during the 2014                 
Ebola epidemic and of those four only one man died. This variation in fatalities leaves much to                 
be desired in the public health and epidemic sector of the affected West African countries and                
begs the question: What are West African countries doing wrong?  
In answering this question one must consider first of all that West Africans are              
intrinsically superstitious. These epidemics originate in rural areas where most people still            
believe that a lot of disease are the manifestations of the wrath of the gods. In the cities where                   
one might expect to find the learned and more knowledgeable members of the society, things are                
only slightly better. As the tales of a disease that is ravaging the people of Liberia, Guinea, and                  
Senegal begin to spread, panic ensues and stories begin to spring up about ways to protect                
yourself from the disease.​56 During the last Ebola epidemic (2014) a lot of people tried               
everything from bathing with salt water twice a day to drinking an assortment of herbal               






rumblings began of a Lassa fever epidemic in Nigeria, people stopped eating “bushmeat”.​57             
Bush meat, which is the West African term for wild game, includes a variety of animals from                 
mammals to reptiles. These animals are hunted, roasted, and sold to highest bidder.​57 No one               
thinks to check if the animal was sick before it was killed, or if the exposure to heat was long and                     
intense enough to kill all living microbes in the meat.​57 Unfortunately, many of these microbes               
could have variations of heat shock proteins that might be able to withstand such temperature               
extremes, in which case the meat is still dangerous even after it's been roasted.​57 But the people                 
cannot be faulted because they do not know any better. Their response is one of ignorance                
because the public health infrastructure of many of these countries are subpar and lack awareness               
schemes.​58 One way to increase awareness is to create fact sheets that can be distributed in                
schools, work places, and general social gatherings that give key details about these diseases and               
how to respond to and prevent the spread of infection*. 
To further put things in perspective, about 100,000 to 300,000 reported cases and 5,000              
deaths from Lassa Fever might not seem significant in the large scheme of things considering               
there are over 7 billion people in the world today.​4 However, of those 7 billion people, 245                 
million of them live in West Africa, and of those West Africans 5,000 people die annually from                 
this disease.​6 A recent study has estimated 22 million people distributed in areas of Central and                
West Africa to be at risk of Ebola. It is also important to understand the fact that these death toll                    
numbers are not a completely accurate representation because many of the people affected by the               
disease do not have access to medical care and thus cannot be counted among the reported cases.                 
Yet, nothing tangible is being done to address the situation. Hopefully, the research presented in               
this paper will lay the framework for more investigations and begin a much-needed conversation. 
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